The institutional cluster is dominated by passive/index rebalancers (BlackRock, State Street, Geode) with no activist or high-conviction hedge fund participation and no insider buying. Monitor for FDA feedback on silevertinib's pivotal path expected in Q4 2026 as the next real catalyst.
Executive Summary
Eight institutional investors, led by BlackRock, State Street, and Geode, collectively doubled or added to their BDTX positions in Q2 2026, increasing aggregate holdings by $7.0M to $11.6M. This cluster follows the company's Q2 earnings release highlighting positive Phase 2 silevertinib data (60% ORR, 86% CNS ORR) and a cash runway into 2H 2028, but the signal is weakened by the dominance of mega-passive index funds and the absence of any insider open-market buying.
Key Financial Metrics
Institutional Positions
Net institutional flow: $7.0M
▲ Buyers (8)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| BlackRock | DOUBLED | +253.9% | $7.2M | $4.9M |
| State Street | DOUBLED | +145.9% | $971.0K | $516.0K |
| Geode | DOUBLED | +127% | $2.3M | $1.1M |
Key Facts
- 8 institutional buyers in Q2 2026, 0 sellers
- Aggregate holdings increased by $7.0M to $11.6M
- BlackRock doubled its position to $7.2M (largest holder)
- All 8 buyers are mega-passive or asset managers — no activist or hedge fund names
- No insider open-market buying in the same window (confluence score 33/100)
- Cluster follows Q2 2026 earnings with positive Phase 2 silevertinib data and cash runway into 2H 2028
Financial Impact
8 institutions accumulated $7.0M in net new positions, bringing total disclosed holdings to $11.6M
Risk Factors
- Passive/index fund buying may reverse on next rebalance
- No insider buying suggests management does not see current valuation as compelling
- Historical pattern of poor stock performance following positive catalysts
- Clinical-stage biotech binary risk — FDA feedback in Q4 2026 is uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-BDTX-2026-Q2 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 10w ago | Institutional Cluster | $2.05 $2.06 | ▲ +0.49% | ▲ +1.16% | — |
Aug 5, 2026 11w ago | 8-K | $1.92 $1.95 | ▲ +1.56% | ▲ +0.95% | — |
May 21, 2026 22w ago | 8-K | $2.28 $2.33 | ▲ +2.19% | ▲ +1.61% | — |
May 21, 2026 22w ago | Press Release | $2.28 $2.33 | ▲ +2.19% | ▲ +1.61% | — |
May 7, 2026 24w ago | 8-K | $2.72 $2.99 | ▲ +9.93% | ▲ +9.10% | — |
Apr 21, 2026 26w ago | Press Release | $3.15 $3.35 | ▲ +6.35% | ▲ +5.33% | — |
Mar 16, 2026 32w ago | Press Release | $2.23 $2.17 | ▼ −2.69% | ▼ −1.29% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers